[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sexually-transmitted-infections-stis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sexually-transmitted-infections-stis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,55,85,115,136,157,176],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100586764","phase-3-sti-testing-to-enhance-prep-use-in-pregnancy-100586764",false,"NCT06919614","STI Testing to Enhance PrEP Use in Pregnancy","Improving PrEP Outcomes Among Pregnant Women in Botswana With an Integrated STI Testing and PrEP Delivery Model","STEP-UP","Inclusion Criteria:\n\n* Pregnant and seeking antenatal care\n* Self-identifying as a cis-gender woman\n* Living without HIV\n* Not currently using PrEP\n* Planning to remain in the city\u002Ftown of enrolment until 9 months post-delivery.\n* Planning to receive antenatal and postnatal care in the city\u002Ftown of enrolment.\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Male gender\n* Not pregnant\n* Living with HIV\n* Currently using PrEP\n* Not planning to remain in the city\u002Ftown of enrolment until 9 months post-delivery\n* Not planning to receive antenatal and postnatal care in the city\u002Ftown to enrolment\n* Not able or willing to provide informed consent for participation",true,"FEMALE",{"count":20,"type":21},600,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The investigators are conducting a study in Botswana to see if offering STI testing along with expanded HIV prevention options (PrEP) helps more pregnant women start and continue using PrEP during and after pregnancy. Pregnant women (n=600) seeking antenatal care in Botswana will be enrolled and randomly assigned to receive the standard of care (standard STI assessment with no STI testing) versus STI testing for Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis during pregnancy and postpartum. The investigators' hypothesis is that providing STI testing alongside PrEP offer will encourage more women to start and continue using PrEP.",[27,28,29],"PrEP Adherence","Sexually Transmitted Infections (STIs)","Pregnancy",[31,32,33,34,35,36,37,38,39,40,41],"Pregancy","PrEP","HIV","STIs","Chlamydia","Gonorrhoea","Gonorrhea","Trichomonas","Dapivirine","Truvada","Oral PrEP","RECRUITING","2026-06-09",{"date":45,"type":46},"2026-06-11","ACTUAL",{"date":48,"type":46},"2025-06-18",{"date":50,"type":21},"2029-08-31",{"name":52,"class":53},"Botswana Harvard AIDS Institute Partnership","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":18,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100572833","phase-4-doxycycline-prophylaxis-for-prevention-of-sexually-transmitted-infections-100572833","NCT06738407","Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections","Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections Among Adolescent and Young Adult Females in the United States","Inclusion Criteria:\n\n* Age 13-29 years, inclusive;\n* Self-reports GC, CT, and\u002For early syphilis diagnosis in the 12 months prior to screening;\n* Self-reports condomless (oral, vaginal, and\u002For anal) intercourse at least once in the 30 days prior to screening\n* Is at least 45 kilograms (99.2 pounds) in weight\n* Fluent in English (able to read, speak, and understand English);\n* Willing to undergo all required study procedures; and\n* Willing to provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Is male;\n* Is pregnant, breastfeeding, or planning to become pregnant in the next 12 months;\n* Documented history of tetracycline allergy or self-reports an allergy to tetracyclines;\n* Current or anticipated use of a medication (e.g., barbiturates, phenytoin, lithium, carbamazepine, systemic retinoids, warfarin) with a contraindicated interaction to doxycycline ;\n* Current or planned use of doxycycline for a prolonged period (\\> 2 weeks) in the 30 days prior to enrollment, including current prescription for doxycycline for STI prophylaxis;\n* Prolonged antibiotic use (\\> 2 weeks) within the last 30 days prior to enrollment;\n* Co-enrollment in any other concurrent interventional research or studies that may interfere with this study, such as an STI prevention trial, unless approved by Protocol Team in writing;\n* Does not have consistent access (or anticipated weekly access for 52 weeks of survey completion) to smartphone that can access the HMP app; or\n* Any other medical condition, medical\u002Fbehavioral intervention, or other conditions that, in the opinion of the clinical site Project Lead (PL)\u002FInvestigator of Record (IoR) or designee, could interfere with adherence to study procedures or compromise interpretation of study results.","13 Years","29 Years",{"count":65,"type":21},760,[67],"PHASE4","The goal of this open-label, randomized trial is to assess the efficacy of doxycycline prophylaxis in reducing incidences of bacterial sexually transmitted infections (STIs) among adolescent and young adult females while also evaluating acceptability and antimicrobial resistance in order to inform public health policy.",[37,35,70,28],"Syphilis",[72,34,73,74],"Sexually Transmitted Infections","Doxycycline Prophylaxis","Doxycycline","2026-05-12",{"date":77,"type":46},"2026-05-15",{"date":79,"type":46},"2026-02-27",{"date":81,"type":21},"2028-06-15",{"name":83,"class":53},"Westat",13,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":92,"minAge":93,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":98,"conditions":99,"keywords":104,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":54},"100632143","integrating-sexual-pleasure-into-harm-reduction-services-for-men-who-have-sex-with-men-and-transgender-persons-who-engage-in-chemsex-or-substance-use-in-thailand-100632143","NCT07509853","Integrating Sexual Pleasure Into Harm Reduction Services for Men Who Have Sex With Men and Transgender Persons Who Engage in Chemsex or Substance Use in Thailand","PLEASURE","Inclusion Criteria:\n\n* MSM, transgender women, transgender men, or non-binary persons\n* Age ≥18 years\n* Engaged in chemsex or substance use within past 12 months\n* Able to provide informed consent\n\nExclusion Criteria:\n\n• Unable to communicate in Thai sufficiently to complete study procedures","ALL","18 Years",{"count":95,"type":21},300,[97],"NA","The study evaluates the integration of a sexual pleasure-based approach into harm reduction services for MSM and transgender persons engaging in chemsex or substance use in Thailand, using the \"Pleasuremeter\" tool to improve sexual health and related outcomes.",[100,101,102,28,103],"HIV Prevention","Substance Use","Mental Health","Chemsex",[105],"PrEP, Harm reduction, Chemsex, Transgender, Sexual pleasure","2026-04-02",{"date":108,"type":46},"2026-04-08",{"date":110,"type":46},"2025-05-01",{"date":112,"type":21},"2028-05-01",{"name":114,"class":53},"Institute of HIV Research and Innovation Foundation, Thailand",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":92,"minAge":93,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":54},"100632374","the-implementation-of-a-trans-tailored-harm-reduction-service-for-transgender-persons-in-relation-to-chemsex-and-substance-use-it-rex-100632374","NCT07512856","The Implementation of a Trans-tailored Harm Reduction Service for Transgender Persons in Relation to chemsEX and Substance Use (iT-REX)","Inclusion Criteria:\n\n* Self-identified transgender women, transgender men, or non-binary persons\n* Age ≥18 years\n* HIV-negative\n* Engaged in chemsex or substance use within past 12 months\n* Able to provide informed consent\n\nExclusion Criteria:\n\n• Inability to communicate in Thai sufficiently to complete study procedures",{"count":122,"type":21},140,[97],"This study evaluates a comprehensive transgender-tailored harm reduction service for transgender women, transgender men, and non-binary individuals engaging in chemsex or substance use in Thailand, focusing on PrEP uptake, HIV\u002FSTI outcomes, mental health, and socio-legal impacts.",[100,101,126,28,103],"Mental Health Disorders",[128],"PrEP, Harm reduction, Chemsex, Transgender",{"date":130,"type":46},"2026-04-06",{"date":132,"type":46},"2024-02-01",{"date":134,"type":21},"2028-02-01",{"name":114,"class":53},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":17,"sex":143,"minAge":93,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":147,"conditions":148,"keywords":149,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":151,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":54},"100632375","host-led-harm-reduction-approach-among-men-who-have-sex-with-men-who-engaged-in-chemsex-in-bangkok-thailand-a-pre-implementation-study-100632375","NCT07512869","Host Led Harm Reduction Approach Among Men Who Have Sex With Men Who Engaged in Chemsex in Bangkok, Thailand: A Pre-Implementation Study","HAMMOCK","Inclusion Criteria:\n\n* MSM aged ≥18 years\n* Able to communicate in Thai\n* Specific by group:\n\n  * Chemsex hosts: hosted ≥2 times in past 6 months\n  * Chemsex guests: attended ≥2 times in past 6 months\n  * CSO \u002F hospital \u002F police staff: working ≥3 months in related roles\n* Provide informed consent\n\nExclusion Criteria:\n\n• Unable to provide informed consent (e.g., under substance influence at consent)","MALE",{"count":145,"type":21},76,"OBSERVATIONAL","This study evaluates the pre-implementation phase of a host-led harm reduction model for men who have sex with men (MSM) engaging in chemsex in Bangkok, Thailand, focusing on understanding harms, contexts, and needs to develop a tailored intervention.",[100,101,102,28],[150],"Chemsex, Harm reduction",{"date":130,"type":46},{"date":153,"type":46},"2025-02-17",{"date":155,"type":21},"2028-12-30",{"name":114,"class":53},{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":17,"sex":92,"minAge":93,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":54},"100631837","pre-implementation-study-to-develop-trans-tailored-services-for-transgender-persons-in-relation-to-chemsex-100631837","NCT07505875","Pre-implementation Study to Develop Trans-tailored Services for Transgender Persons in Relation to chemsEX","T-REX","Inclusion Criteria:\n\n* Age ≥18 years\n* Able to communicate in Thai\n* Provide informed consent\n\nExclusion Criteria:\n\n• Unable to participate in in-depth interview (IDI) (online or onsite)",{"count":165,"type":21},50,"The study is a pre-implementation cross-sectional study exploring chemsex behaviors among transgender persons and gathering perspectives from multiple stakeholders to inform the development of transgender-tailored harm reduction services.",[101,100,28],[150],"2026-03-31",{"date":130,"type":46},{"date":172,"type":46},"2024-05-01",{"date":174,"type":21},"2027-05-01",{"name":114,"class":53},{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":17,"sex":92,"minAge":183,"maxAge":4,"enrollmentInfo":184,"targetDuration":186,"studyType":146,"phases":4,"briefSummary":187,"conditions":188,"keywords":189,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":204},"100582256","development-of-a-predictive-model-for-sexually-transmitted-infections-in-individuals-using-pre-exposure-prophylaxis-for-hiv-in-spain-100582256","NCT06860945","Development of a Predictive Model for Sexually Transmitted Infections in Individuals Using Pre-Exposure Prophylaxis for HIV in Spain","STI_PrEPare","Inclusion Criteria:\n\n* All individuals with documented initiation of oral PrEP (daily or event-driven regimens), who have collected the medication at least once and have taken at least one pill, will be included in the study.\n\nThe approved criteria for the use of oral PrEP in Spain, as recommended by the Spanish Gesida guidelines (GeSIDA. Recomendaciones sobre la Profilaxis Pre-Exposición para la Prevención de la Infección por VIH en España. Marzo 2023. Available at http:\u002F\u002F.gesida-seimc.org\u002Fcategory\u002Fguias-clinicas\u002Fotras-guias-vigentes\u002F), are as follows:\n\n* People without HIV infection at the time of cohort inclusion\n* Age ≥ 16 yr who meet the following criteria:\n* MSM and transgender women with at least two of the following criteria during the last year: \\> 10 sexual partners; Condomless anal sex; Chemsex; PEP; ≥ 1 STI\n* Sex worker women who report non-habitual use of condoms.\n* Cisgender males\u002Ffemales, who report condomless and present at least two of the same criteria as MSM and transgender.\n* PWID with unsafe injection practices\n\nExclusion Criteria: none\n\n\\-","16 Years",{"count":185,"type":21},9000,"5 Years","Objective: To develop and validate a predictive model for acquiring sexually transmitted infections (STIs) in individuals using HIV pre-exposure prophylaxis (PrEP) within the national program providing this strategy.\n\nMethods: Ambispective cohort study, multicentric (23 Spanish hospitals). All PrEP users, with follow-up within the program, will be included. Entry into the program will be considered as the baseline visit. From there, patients are followed quarterly, following the national protocols for monitoring PrEP users in Spain. At each visit, diagnosis of different STIs (serum, pharyngeal swab, urethral or urine sample, rectal swab, endocervical\u002Fvaginal swab, ulcer) is performed. Primary outcome variable: development of an STI (Yes\u002FNo). The following STIs will be considered: syphilis, Neisseria gonorrhoeae (NG) infection, Chlamydia trachomatis (CT) infection, lymphogranuloma venereum (LGV), Mycoplasma genitalium (MG) infection, genital herpes, hepatitis A, hepatitis B, hepatitis C, HIV infection, and MPOX. Secondary outcome variable: number of diagnosed STIs. In order to determine factors associated with acquiring an STI, multivariate analyses will be conducted using logistic regression. The best models will be analyzed in the validation population. To compare the models, we will follow the Bayesian approach suggested by Benavoli et al.",[28,33,32],[190,33,32,191,192,193,194],"STI","modelling","machine learning","adherence","persistence","2025-02-28",{"date":197,"type":46},"2025-03-06",{"date":199,"type":46},"2025-01-01",{"date":201,"type":21},"2026-01-01",{"name":203,"class":53},"Hospital Universitario de Valme",26]